🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Homozygosity for the PNPLA3 risk allele is linked to liver fat accumulation. In phase 1 trials, JNJ-75220795, a hepatocyte-targeted GalNAc-conjugated PNPLA3 siRNA, reduced liver fat in PNPLA3 I148M homozygous patients with MAFLD. Full correspondence: nej.md/3LMHys4

SIETE NELLA STORIA. SIETE NELL'OLIMPOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOO #HomeOfTheOlympics #Paris2024 #ItalVolley #Volleyball #Pallavolo

Check-out our last article! 🔽 β-blockers lower first decompensation in patients with cirrhosis and enduring portal hypertension after etiological treatment. @MadalinaTaru Horia Stefanescu bogdan procopet The Baveno Cooperation: an EASL Consortium cghjournal.org/article/S1542-…

Alcohol intake is key to determining prognosis in alcohol-related liver disease, but measuring intake is challenging! Is PEth the best tool, or does self-reporting still matter? JHEP Reports Emil Deleuran Hansen Aleksander Krag sciencedirect.com/science/articl…

The authors of today's #readoftheweek📚discuss how sarcopenia on computed tomography is associated with a 2-fold higher risk of mortality in patients with cirrhosis. Read here this JHEP Reports article: jhep-reports.eu/article/S2589-… 🙏 Elton Dajti, Annalisa Berzigotti, Susana Rodrigues,

Thrilled to have this work out in HEPATOLOGY Journal ! Short version: The problem - it’s hard to diagnose minimal HE or predict future overt HE in clinic What we found - automated speech analysis can do both

🚨#livertwitter #SpleenStiffness Measurement #SSM by dedicated 100Hz #VCTE #Fibroscan probe improves #PortalHypertension risk assessment 🎯 #NICER model by Mathias Jachs Mattias Mandorfer for the The Baveno Cooperation: an EASL Consortium published The Lancet Gastroenterology & Hepatology 📕t.ly/bL_wv

What a week for non-invasive tests and portal hypertension! Excellent study and congratulations to Mattias Mandorfer and Mathias Jachs for coordinating this landmark study!

🚨🚨Happy to share our last paper!!!🚨🚨 Non-invasive assessment of severe liver fibrosis in patients with Fontan-associated liver disease: The VALDIG-EASL FONLIVER cohort - Journal of Hepatology journal-of-hepatology.eu/article/S0168-…

Hepatocellular Cancer Surveillance in Patients with Advanced Chronic Liver Disease | NEJM Evidence evidence.nejm.org/doi/full/10.10…

Congratulations on this important trial Sunil Taneja

Our best work so far! nature.com/articles/s4159…

Honored to share our recently published paper in Nature Medicine🔥shedding light on MASLD heterogeneity #LiverTwitter AASLD EASLnews 🗝️2 types of at-risk MASLD: same liver histology, distinct clinical trajectories and biological profiles 👉nature.com/articles/s4159…

🚨 It is finally here‼️ 📜 Carvedilol vs. Propranolol for preventing decompensation and mortality in compensated & decompensated cirrhosis 📎 journal-of-hepatology.eu/article/S0168-… 🫂 Huge thanks to all coauthors! 🙌

What’s the best way to implement the 2-step clinical care pathway for evaluating MASLD? Is it as effective as VCTE for all patients? Check out this paper in J Hep: authors.elsevier.com/sd/article/S01…. Congrats to Terry Cheuk-Fung Yip and the VCTE-Prognosis Study Team! 🎉 #MASLD #ClinicalResearch

New research - Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia: interim results from the ATTENTION RCT thelancet.com/journals/langa… #LiverTwitter #MedTwitter

🇳🇱 Join us at #EASL2025 in Amsterdam 🇳🇱 📅 Thu 08 May 08:30–09:45 | Future of Hepatology: Endohepatology 10:00–10:30 | Baveno @ EASL Track Hub (Cirrhosis & Complications) 📅 Fri 09 May 12:00–13:30 | Baveno General Assembly (Room D201, members only) #LiverTwitter